女性HIV感染者使用整合酶链转移抑制剂与体重增加相关
本研究基于妇女跨机构HIV研究(WIHS)2006-2017年数据,比较换用或加用整合酶链转移抑制剂(INSTI)的1118名女性HIV感染者与继续非INSTI方案者的体测变化。结果显示,INSTI组体重、BMI、体脂百分比及多个部位围度增幅显著更大,且不同INSTI类型间无差异。
要点
- 女性HIV感染者换用或加用INSTI后体重、BMI、体脂及腰臀臂腿围度增幅显著高于非INSTI组。
- 不同INSTI类型间上述体测指标变化幅度无差异。
- 需进一步研究这些体测变化的代谢及健康影响。
核心结论
- 在女性HIV感染者中,换用INSTI与非INSTI抗逆转录病毒治疗相比,与体重、体围和脂肪百分比显著增加相关。
研究设计与样本
- 研究纳入2006-2017年妇女跨机构HIV研究(WIHS)中1118名女性(234名换用/加用INSTI组,884名继续非INSTI组),平均随访2.0年(标准差±0.1),平均年龄48.8岁(标准差±8.8),61%为黑人。
主要发现
- 不同INSTI类型间上述变化幅度无差异。
临床怎么用
- 对女性HIV感染者换用或加用INSTI时,应关注体重及体脂变化,并监测代谢相关指标。
局限性
- 研究为观察性设计,可能存在残留混杂;原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Integrase strand-transfer inhibitor (INSTI)-based antiretroviral therapy (ART) is recommended for human immunodeficiency virus (HIV) management. Although studies have suggested associations between INSTIs and weight gain, women living with HIV (WLHIV) have been underrepresented in research. We evaluated the effect of switching or adding INSTIs among WLHIV. METHODS: Women enrolled in the Women's Interagency HIV Study (WIHS) from 2006-2017 who switched to or added an INSTI to ART (SWAD group) were compared to women on non-INSTI ART (STAY group). Body weight, body mass index (BMI), percentage body fat (PBF), and waist, hip, arm, and thigh circumferences were measured 6-12 months before and 6-18 months after the INSTI switch/add in SWAD participants, with comparable measurement time points in STAY participants. Linear regression models compared changes over time by SWAD/STAY group, adjusted for age, race, WIHS site, education, income, smoking status, and baseline ART regimen. RESULTS: We followed 1118 women (234 SWAD and 884 STAY) for a mean of 2.0 years (+/- 0.1 standard deviation [SD]; mean age 48.8 years, SD +/- 8.8); 61% were Black. On average, compared to the STAY group, the SWAD group experienced mean greater increases of 2.1 kg in body weight, 0.8 kg/m2 in BMI, 1.4% in PBF, and 2.0, 1.9, 0.6, and 1.0 cm in waist, hip, arm, and thigh circumference, respectively (all P values < .05). No differences in magnitudes of these changes were observed by INSTI type. CONCLUSIONS: In WLHIV, a switch to INSTI was associated with significant increases in body weight, body circumferences, and fat percentages, compared to non-INSTI ART. The metabolic and other health effects of these changes deserve further investigation.
引用
- Kerchberger AM, Sheth AN, Angert CD, et al. Weight Gain Associated With Integrase Stand Transfer Inhibitor Use in Women. Clin Infect Dis. 2020. PMID: 31504324. doi:10.1093/cid/ciz853
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。